Literature DB >> 15788043

Antipsychotic depot medication and attitudes of community psychiatric nurses.

M X Patel1, N DE Zoysa, D Baker, A S David.   

Abstract

Utilization of long-acting antipsychotic injections (depots) shows wide regional variation. In many countries, community psychiatric nurses (CPNs) administer depots but their concerns and attitudes regarding these drugs are seldom considered. We aimed to investigate attitudes and knowledge towards depots in a cross-sectional survey of CPNs in London, and compare them with those of psychiatrists obtained in a previous study. Three subscales of a depot attitude/knowledge questionnaire were used with additional items which referred to aspects of the CPN role. Participants were 70 CPNs who attended an academic meeting. Most CPNs reported that they were involved in treatment decisions (78%) although some CPNs seldom asked their patients about side effects (19%) and felt that they did not have sufficient time for consultations (23%) or training (23%). Several CPNs believed that depots are old fashioned (34%) and stigmatizing (44%). Compared to psychiatrists, CPNs believed more that depots compromised patient autonomy (28%, P = 0.003) and were coercive (42%, P < 0.001). Familiarity with depots and their knowledge of side effects were positively associated with favourable attitudes. CPNs have several strongly endorsed attitudes towards depot medication. Interprofessional group differences also exist which may undermine the treatment process. Training/refresher courses about depots should highlight systematic treatment decision-making and side effect monitoring which, in turn, may improve professionals' attitudes, knowledge and clinical monitoring of depots.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788043     DOI: 10.1111/j.1365-2850.2004.00826.x

Source DB:  PubMed          Journal:  J Psychiatr Ment Health Nurs        ISSN: 1351-0126            Impact factor:   2.952


  15 in total

1.  WPA guidance on how to combat stigmatization of psychiatry and psychiatrists.

Authors:  Norman Sartorius; Wolfgang Gaebel; Helen-Rose Cleveland; Heather Stuart; Tsuyoshi Akiyama; Julio Arboleda-Flórez; Anja E Baumann; Oye Gureje; Miguel R Jorge; Marianne Kastrup; Yuriko Suzuki; Allan Tasman
Journal:  World Psychiatry       Date:  2010-10       Impact factor: 49.548

Review 2.  Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.

Authors:  Daniel Luedecke; Daniel Schöttle; Anne Karow; Martin Lambert; Dieter Naber
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

3.  Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence.

Authors:  Katarina Kelin; Alan Jm Brnabic; Richard Newton; Raúl I Escamilla; Liang-Jen Chuo; Malina Simu; Wenyu Ye; William Montgomery; Jamie Karagianis; Haya Ascher-Svanum
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

4.  The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria.

Authors:  Bawo O James; Joyce O Omoaregba; Kingsley M Okonoda; Edebi U Otefe; Maxine X Patel
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

Review 5.  Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.

Authors:  Pierre Chue; Robin Emsley
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.

Authors:  Heidi J Wehring; Sheryl Thedford; Maju Koola; Deanna L Kelly
Journal:  J Cent Nerv Syst Dis       Date:  2011-06-01

7.  Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses.

Authors:  Paul Geerts; Guadalupe Martinez; Andreas Schreiner
Journal:  BMC Psychiatry       Date:  2013-02-17       Impact factor: 3.630

8.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

Review 9.  Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile.

Authors:  Monica Zolezzi; Rawan Abouelhassan; Yassin Eltorki; Peter M Haddad; Mahtab Noorizadeh
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-14       Impact factor: 2.570

10.  Working alliance and its relationship to outcomes in a randomized controlled trial (RCT) of antipsychotic medication.

Authors:  Til Wykes; Diana Rose; Paul Williams; Anthony S David
Journal:  BMC Psychiatry       Date:  2013-01-15       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.